Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd ™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE NEWSWIRE) ...
Quantum computing stocks are lagging behind the broader market in 2026. Don’t panic just yet.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303534840/en/ The articles, information, and content displayed on this webpage ...
Over the course of 2025, D-Wave Quantum QBTS moved noticeably from purely research-oriented results toward measurable revenue traction as its quantum systems began generating meaningful top-line ...
Quantum Computing (NASDAQ: QUBT) stock went through volatile trading across 2025 and ended the year deeply in the red. The company's share price sank 38% across the stretch, according to data from S&P ...
Quantum computing stocks are in full rebound mode in 2026, with the benchmark S&P Kensho Global Quantum Computing ...
D-Wave Quantum (NYSE: QBTS) certainly had an extraordinary run over the past couple of years. For investors who didn't have ...
As one of the world's most intriguing emerging technologies, quantum computing will draw investors who are looking at ...
PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), the only dual-platform quantum computing company, providing both annealing and gate-model systems, software, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results